25 XP   0   0   10

Sangamo Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Sangamo together

PenkeI guess you are interested in Sangamo Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sangamo Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Sangamo Therapeutics Inc

I send you an email if I find something interesting about Sangamo Therapeutics Inc.

Quick analysis of Sangamo (30 sec.)










What can you expect buying and holding a share of Sangamo? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.46
Expected worth in 1 year
$-0.72
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$-1.19
Return On Investment
-176.9%

For what price can you sell your share?

Current Price per Share
$0.67
Expected price per share
$0.2911 - $1.6187
How sure are you?
50%

1. Valuation of Sangamo (5 min.)




Live pricePrice per Share (EOD)

$0.67

Intrinsic Value Per Share

$-22.15 - $-9.01

Total Value Per Share

$-21.69 - $-8.55

2. Growth of Sangamo (5 min.)




Is Sangamo growing?

Current yearPrevious yearGrowGrow %
How rich?$82.8m$314.2m-$117.4m-59.7%

How much money is Sangamo making?

Current yearPrevious yearGrowGrow %
Making money-$64.4m-$48m-$16.3m-25.4%
Net Profit Margin-1,430.8%-173.6%--

How much money comes from the company's main activities?

3. Financial Health of Sangamo (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#416 / 1031

Most Revenue
#145 / 1031

Most Profit
#951 / 1031

Most Efficient
#843 / 1031

What can you expect buying and holding a share of Sangamo? (5 min.)

Welcome investor! Sangamo's management wants to use your money to grow the business. In return you get a share of Sangamo.

What can you expect buying and holding a share of Sangamo?

First you should know what it really means to hold a share of Sangamo. And how you can make/lose money.

Speculation

The Price per Share of Sangamo is $0.6702. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sangamo.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sangamo, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.46. Based on the TTM, the Book Value Change Per Share is $-0.30 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sangamo.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.34-50.3%-0.36-53.8%-0.27-40.1%-0.24-35.2%-0.15-23.1%
Usd Book Value Change Per Share-0.29-43.4%-0.30-44.2%-0.11-16.8%-0.08-11.8%-0.01-0.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.29-43.4%-0.30-44.2%-0.11-16.8%-0.08-11.8%-0.01-0.8%
Usd Price Per Share0.54-1.05-4.50-7.07-9.22-
Price to Earnings Ratio-0.40-0.64--4.26--16.09--33.77-
Price-to-Total Gains Ratio-1.87-0.63--51.67--19.86-29.75-
Price to Book Ratio1.17-0.98-2.54-3.15-6.41-
Price-to-Total Gains Ratio-1.87-0.63--51.67--19.86-29.75-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.6702
Number of shares1492
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.30-0.08
Usd Total Gains Per Share-0.30-0.08
Gains per Quarter (1492 shares)-442.15-118.27
Gains per Year (1492 shares)-1,768.58-473.07
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1769-17790-473-483
20-3537-35480-946-956
30-5306-53170-1419-1429
40-7074-70860-1892-1902
50-8843-88550-2365-2375
60-10611-106240-2838-2848
70-12380-123930-3312-3321
80-14149-141620-3785-3794
90-15917-159310-4258-4267
100-17686-177000-4731-4740

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%2.018.00.010.0%2.038.00.05.0%2.094.00.02.1%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%5.015.00.025.0%11.029.00.027.5%20.076.00.020.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.096.00.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%5.015.00.025.0%11.029.00.027.5%20.076.00.020.8%

Fundamentals of Sangamo

About Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Fundamental data was last updated by Penke on 2024-03-18 17:50:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Sangamo Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Sangamo earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Sangamo to the Biotechnology industry mean.
  • A Net Profit Margin of -2,952.8% means that $-29.53 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sangamo Therapeutics Inc:

  • The MRQ is -2,952.8%. The company is making a huge loss. -2
  • The TTM is -1,430.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,952.8%TTM-1,430.8%-1,522.0%
TTM-1,430.8%YOY-173.6%-1,257.1%
TTM-1,430.8%5Y-426.4%-1,004.3%
5Y-426.4%10Y-308.6%-117.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,952.8%-159.2%-2,793.6%
TTM-1,430.8%-202.3%-1,228.5%
YOY-173.6%-263.0%+89.4%
5Y-426.4%-452.4%+26.0%
10Y-308.6%-589.0%+280.4%
1.1.2. Return on Assets

Shows how efficient Sangamo is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sangamo to the Biotechnology industry mean.
  • -36.5% Return on Assets means that Sangamo generated $-0.36 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sangamo Therapeutics Inc:

  • The MRQ is -36.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -28.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-36.5%TTM-28.6%-7.9%
TTM-28.6%YOY-8.0%-20.6%
TTM-28.6%5Y-10.0%-18.6%
5Y-10.0%10Y-7.7%-2.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-36.5%-12.5%-24.0%
TTM-28.6%-12.2%-16.4%
YOY-8.0%-11.2%+3.2%
5Y-10.0%-13.3%+3.3%
10Y-7.7%-14.6%+6.9%
1.1.3. Return on Equity

Shows how efficient Sangamo is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sangamo to the Biotechnology industry mean.
  • -72.7% Return on Equity means Sangamo generated $-0.73 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sangamo Therapeutics Inc:

  • The MRQ is -72.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -48.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-72.7%TTM-48.2%-24.6%
TTM-48.2%YOY-15.4%-32.8%
TTM-48.2%5Y-17.4%-30.8%
5Y-17.4%10Y-12.1%-5.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-72.7%-16.0%-56.7%
TTM-48.2%-15.8%-32.4%
YOY-15.4%-13.9%-1.5%
5Y-17.4%-18.2%+0.8%
10Y-12.1%-19.1%+7.0%

1.2. Operating Efficiency of Sangamo Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Sangamo is operating .

  • Measures how much profit Sangamo makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sangamo to the Biotechnology industry mean.
  • An Operating Margin of -3,054.0% means the company generated $-30.54  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sangamo Therapeutics Inc:

  • The MRQ is -3,054.0%. The company is operating very inefficient. -2
  • The TTM is -1,101.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-3,054.0%TTM-1,101.5%-1,952.5%
TTM-1,101.5%YOY-191.6%-909.9%
TTM-1,101.5%5Y-371.8%-729.7%
5Y-371.8%10Y-286.0%-85.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,054.0%-299.5%-2,754.5%
TTM-1,101.5%-208.5%-893.0%
YOY-191.6%-280.2%+88.6%
5Y-371.8%-459.9%+88.1%
10Y-286.0%-596.9%+310.9%
1.2.2. Operating Ratio

Measures how efficient Sangamo is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 31.54 means that the operating costs are $31.54 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Sangamo Therapeutics Inc:

  • The MRQ is 31.540. The company is inefficient in keeping operating costs low. -1
  • The TTM is 13.209. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ31.540TTM13.209+18.332
TTM13.209YOY2.877+10.332
TTM13.2095Y5.364+7.844
5Y5.36410Y5.550-0.186
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ31.5402.817+28.723
TTM13.2093.181+10.028
YOY2.8773.609-0.732
5Y5.3645.554-0.190
10Y5.5507.396-1.846

1.3. Liquidity of Sangamo Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Sangamo is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.98 means the company has $1.98 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Sangamo Therapeutics Inc:

  • The MRQ is 1.976. The company is able to pay all its short-term debts. +1
  • The TTM is 2.978. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.976TTM2.978-1.002
TTM2.978YOY2.792+0.186
TTM2.9785Y4.093-1.115
5Y4.09310Y6.780-2.687
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9763.987-2.011
TTM2.9784.440-1.462
YOY2.7925.569-2.777
5Y4.0936.158-2.065
10Y6.7806.492+0.288
1.3.2. Quick Ratio

Measures if Sangamo is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sangamo to the Biotechnology industry mean.
  • A Quick Ratio of 2.47 means the company can pay off $2.47 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sangamo Therapeutics Inc:

  • The MRQ is 2.475. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.209. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.475TTM4.209-1.734
TTM4.209YOY4.387-0.178
TTM4.2095Y6.473-2.264
5Y6.47310Y11.878-5.405
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4753.653-1.178
TTM4.2094.158+0.051
YOY4.3875.515-1.128
5Y6.4736.012+0.461
10Y11.8786.206+5.672

1.4. Solvency of Sangamo Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Sangamo assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sangamo to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.50 means that Sangamo assets are financed with 49.9% credit (debt) and the remaining percentage (100% - 49.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Sangamo Therapeutics Inc:

  • The MRQ is 0.499. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.351. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.499TTM0.351+0.148
TTM0.351YOY0.482-0.131
TTM0.3515Y0.415-0.064
5Y0.41510Y0.312+0.103
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4990.336+0.163
TTM0.3510.330+0.021
YOY0.4820.267+0.215
5Y0.4150.367+0.048
10Y0.3120.378-0.066
1.4.2. Debt to Equity Ratio

Measures if Sangamo is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sangamo to the Biotechnology industry mean.
  • A Debt to Equity ratio of 99.5% means that company has $0.99 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sangamo Therapeutics Inc:

  • The MRQ is 0.995. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.582. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.995TTM0.582+0.413
TTM0.582YOY0.931-0.349
TTM0.5825Y0.737-0.156
5Y0.73710Y0.513+0.224
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9950.376+0.619
TTM0.5820.398+0.184
YOY0.9310.334+0.597
5Y0.7370.431+0.306
10Y0.5130.476+0.037

2. Market Valuation of Sangamo Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Sangamo generates.

  • Above 15 is considered overpriced but always compare Sangamo to the Biotechnology industry mean.
  • A PE ratio of -0.40 means the investor is paying $-0.40 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sangamo Therapeutics Inc:

  • The EOD is -0.497. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.403. Based on the earnings, the company is expensive. -2
  • The TTM is 0.639. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-0.497MRQ-0.403-0.094
MRQ-0.403TTM0.639-1.042
TTM0.639YOY-4.256+4.895
TTM0.6395Y-16.087+16.727
5Y-16.08710Y-33.772+17.685
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.497-2.697+2.200
MRQ-0.403-2.422+2.019
TTM0.639-2.709+3.348
YOY-4.256-4.116-0.140
5Y-16.087-6.257-9.830
10Y-33.772-6.478-27.294
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sangamo Therapeutics Inc:

  • The EOD is -0.563. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.457. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.725. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.563MRQ-0.457-0.107
MRQ-0.457TTM-0.725+0.268
TTM-0.725YOY-3.318+2.593
TTM-0.7255Y-8.333+7.608
5Y-8.33310Y-25.641+17.309
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.563-3.344+2.781
MRQ-0.457-2.939+2.482
TTM-0.725-3.486+2.761
YOY-3.318-5.592+2.274
5Y-8.333-8.464+0.131
10Y-25.641-8.872-16.769
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Sangamo is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.17 means the investor is paying $1.17 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Sangamo Therapeutics Inc:

  • The EOD is 1.447. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.173. Based on the equity, the company is underpriced. +1
  • The TTM is 0.975. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.447MRQ1.173+0.274
MRQ1.173TTM0.975+0.197
TTM0.975YOY2.544-1.568
TTM0.9755Y3.146-2.170
5Y3.14610Y6.408-3.262
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4472.198-0.751
MRQ1.1732.042-0.869
TTM0.9752.121-1.146
YOY2.5442.907-0.363
5Y3.1463.682-0.536
10Y6.4084.114+2.294
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Sangamo Therapeutics Inc.

3.1. Institutions holding Sangamo Therapeutics Inc

Institutions are holding 49.663% of the shares of Sangamo Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Wasatch Advisors Inc.10.14210.0682179867819343415.4792
2023-09-30BlackRock Inc8.90740.000315796956-92020-0.5791
2023-09-30Vanguard Group Inc7.06540.0002125302451318331.0633
2023-09-30Rokos Capital Management LLP3.65070.0286647434800
2023-09-30Citadel Advisors Llc2.5560.00064532915379020.8432
2023-09-30Credit Suisse First Boston (CSFB)2.08630.0023370000000
2023-09-30Geode Capital Management, LLC1.69040.000229979261421744.9785
2023-09-30Acadian Asset Management LLC1.65090.0074292776928230812696.6615
2023-09-30State Street Corporation1.51460.00012686085304581.1469
2023-09-30Hudson Bay Capital Management LP1.46440.00612597000127200096
2023-09-30D. E. Shaw & Co LP1.41450.001625085851246095.2269
2023-09-30Renaissance Technologies Corp1.3340.00242365754-701742-22.8767
2023-09-30ExodusPoint Capital Management, LP1.06590.01081890425-193208-9.2727
2023-09-30Goldman Sachs Group Inc0.91620.0002162492350470145.0537
2023-09-30JPMorgan Chase & Co0.79290.00011406146-76270-5.145
2023-09-30Long Focus Capital Management, LLC0.77360.029413720001000007.8616
2023-09-30Bank of America Corp0.69650.00011235198841460213.7106
2023-09-30Charles Schwab Investment Management Inc0.67170.0002119120225767627.6024
2023-09-30Northern Trust Corp0.6710.00011189947-12022-1.0002
2023-09-30HighTower Advisors, LLC0.64460.00111143140-13725-1.1864
Total 49.70910.1688157345+6111248+6.9%

3.2. Funds holding Sangamo Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Wasatch Ultra Growth4.89770.3948685983-1486733-14.6149
2024-01-31Vanguard Total Stock Mkt Idx Inv2.41430.0001428170000
2024-02-29iShares Russell 2000 ETF1.9860.00663522104-576-0.0164
2023-12-31Vanguard Strategic Small-Cap Equity Inv1.14330.074202761900
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr1.05790.0009187612000
2024-01-31BlackRock Advantage Small Cap Core Instl0.94420.0214167456300
2024-02-01iShares Russell 2000 Value ETF0.9350.007165822020980.1267
2023-12-31Vanguard Explorer Inv0.78670.0036139527000
2023-12-31Fidelity Small Cap Index0.78510.003139233900
2024-01-31JPM Thematics Genetic Thrps C2 Acc USD0.72160.0785127978400
2023-12-31Wasatch Micro Cap0.66560.1019118036200
2024-01-31Fidelity Extended Market Index0.48460.001185944100
2023-12-31Vanguard VIF Small Co Gr0.39660.025370331000
2024-02-29Schwab US Small-Cap ETF™0.39060.004569268800
2024-01-31State St Russell Sm/Mid Cp® Indx NL Cl C0.36060.000863943000
2024-01-31State St Russell Sm Cap® Indx SL Cl I0.31660.002956149000
2024-01-31Vanguard Health Care ETF0.29510.001252341038060.7325
2024-01-31Vanguard Russell 2000 ETF0.29150.0028516912109482.1638
2023-12-31Zacks Small Cap Equity Strategy0.28340.20525026735026730
2023-12-31Vanguard Strategic Equity Inv0.26380.003346793000
Total 19.42020.938134441348-967784-2.8%

3.3. Insider Transactions

Insiders are holding 10.717% of the shares of Sangamo Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-26Biogen Inc.SELL60000000.5

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Sangamo Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.291-0.296+2%-0.112-61%-0.079-73%-0.005-98%
Book Value Per Share--0.4631.100-58%1.756-74%2.038-77%1.617-71%
Current Ratio--1.9762.978-34%2.792-29%4.093-52%6.780-71%
Debt To Asset Ratio--0.4990.351+42%0.482+3%0.415+20%0.312+60%
Debt To Equity Ratio--0.9950.582+71%0.931+7%0.737+35%0.513+94%
Dividend Per Share----0%-0%-0%-0%
Eps---0.337-0.360+7%-0.269-20%-0.236-30%-0.155-54%
Free Cash Flow Per Share---0.297-0.344+16%-0.341+15%-0.211-29%-0.121-59%
Free Cash Flow To Equity Per Share---0.296-0.323+9%-0.222-25%-0.092-69%0.002-14348%
Gross Profit Margin--1.0481.012+4%1.000+5%1.002+5%1.001+5%
Intrinsic Value_10Y_max---9.012--------
Intrinsic Value_10Y_min---22.151--------
Intrinsic Value_1Y_max---0.544--------
Intrinsic Value_1Y_min---1.541--------
Intrinsic Value_3Y_max---1.909--------
Intrinsic Value_3Y_min---5.246--------
Intrinsic Value_5Y_max---3.603--------
Intrinsic Value_5Y_min---9.596--------
Market Cap119902801.200+19%97199629.800187989952.150-48%804629735.000-88%1264132799.930-92%1649303552.715-94%
Net Profit Margin---29.528-14.308-52%-1.736-94%-4.264-86%-3.086-90%
Operating Margin---30.540-11.015-64%-1.916-94%-3.718-88%-2.860-91%
Operating Ratio--31.54013.209+139%2.877+996%5.364+488%5.550+468%
Pb Ratio1.447+19%1.1730.975+20%2.544-54%3.146-63%6.408-82%
Pe Ratio-0.497-23%-0.4030.639-163%-4.256+956%-16.087+3892%-33.772+8280%
Price Per Share0.670+19%0.5431.051-48%4.498-88%7.066-92%9.219-94%
Price To Free Cash Flow Ratio-0.563-23%-0.457-0.725+59%-3.318+627%-8.333+1725%-25.641+5515%
Price To Total Gains Ratio-2.304-23%-1.8680.627-398%-51.672+2666%-19.859+963%29.750-106%
Quick Ratio--2.4754.209-41%4.387-44%6.473-62%11.878-79%
Return On Assets---0.365-0.286-22%-0.080-78%-0.100-73%-0.077-79%
Return On Equity---0.727-0.482-34%-0.154-79%-0.174-76%-0.121-83%
Total Gains Per Share---0.291-0.296+2%-0.112-61%-0.079-73%-0.005-98%
Usd Book Value--82887000.000196765250.000-58%314228750.000-74%364553650.000-77%289336200.000-71%
Usd Book Value Change Per Share---0.291-0.296+2%-0.112-61%-0.079-73%-0.005-98%
Usd Book Value Per Share--0.4631.100-58%1.756-74%2.038-77%1.617-71%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.337-0.360+7%-0.269-20%-0.236-30%-0.155-54%
Usd Free Cash Flow---53209000.000-61499250.000+16%-60949500.000+15%-37812000.000-29%-21594175.000-59%
Usd Free Cash Flow Per Share---0.297-0.344+16%-0.341+15%-0.211-29%-0.121-59%
Usd Free Cash Flow To Equity Per Share---0.296-0.323+9%-0.222-25%-0.092-69%0.002-14348%
Usd Market Cap119902801.200+19%97199629.800187989952.150-48%804629735.000-88%1264132799.930-92%1649303552.715-94%
Usd Price Per Share0.670+19%0.5431.051-48%4.498-88%7.066-92%9.219-94%
Usd Profit---60296000.000-64458000.000+7%-48069500.000-20%-42228900.000-30%-27656450.000-54%
Usd Revenue--2041999.00044057999.750-95%27824750.000-93%30942599.950-93%21116724.975-90%
Usd Total Gains Per Share---0.291-0.296+2%-0.112-61%-0.079-73%-0.005-98%
 EOD+5 -3MRQTTM+15 -19YOY+7 -275Y+4 -3010Y+3 -31

4.2. Fundamental Score

Let's check the fundamental score of Sangamo Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.497
Price to Book Ratio (EOD)Between0-11.447
Net Profit Margin (MRQ)Greater than0-29.528
Operating Margin (MRQ)Greater than0-30.540
Quick Ratio (MRQ)Greater than12.475
Current Ratio (MRQ)Greater than11.976
Debt to Asset Ratio (MRQ)Less than10.499
Debt to Equity Ratio (MRQ)Less than10.995
Return on Equity (MRQ)Greater than0.15-0.727
Return on Assets (MRQ)Greater than0.05-0.365
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Sangamo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.570
Ma 20Greater thanMa 500.837
Ma 50Greater thanMa 1000.773
Ma 100Greater thanMa 2000.605
OpenGreater thanClose0.625
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets165,320
Total Liabilities82,433
Total Stockholder Equity82,887
 As reported
Total Liabilities 82,433
Total Stockholder Equity+ 82,887
Total Assets = 165,320

Assets

Total Assets165,320
Total Current Assets94,328
Long-term Assets70,992
Total Current Assets
Cash And Cash Equivalents 45,204
Short-term Investments 35,798
Net Receivables 1,326
Other Current Assets 12,000
Total Current Assets  (as reported)94,328
Total Current Assets  (calculated)94,328
+/-0
Long-term Assets
Property Plant Equipment 52,865
Long-term Assets Other 16,627
Long-term Assets  (as reported)70,992
Long-term Assets  (calculated)69,492
+/- 1,500

Liabilities & Shareholders' Equity

Total Current Liabilities47,731
Long-term Liabilities34,702
Total Stockholder Equity82,887
Total Current Liabilities
Short-term Debt 4,589
Accounts payable 15,259
Other Current Liabilities 27,883
Total Current Liabilities  (as reported)47,731
Total Current Liabilities  (calculated)47,731
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt33,515
Long-term Liabilities Other 1,187
Long-term Liabilities  (as reported)34,702
Long-term Liabilities  (calculated)34,702
+/-0
Total Stockholder Equity
Common Stock1,781
Retained Earnings -1,406,376
Accumulated Other Comprehensive Income -4,595
Other Stockholders Equity 1,492,077
Total Stockholder Equity (as reported)82,887
Total Stockholder Equity (calculated)82,887
+/-0
Other
Capital Stock1,781
Cash and Short Term Investments 81,002
Common Stock Shares Outstanding 177,619
Liabilities and Stockholders Equity 165,320
Net Debt -7,100
Net Invested Capital 82,887
Net Working Capital 46,597
Property Plant and Equipment Gross 103,911
Short Long Term Debt Total 38,104



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-31
> Total Assets 
22,950
69,793
69,057
68,925
67,942
65,500
86,896
85,017
80,717
77,203
56,028
56,227
52,720
50,045
48,101
46,232
43,266
40,361
36,358
34,725
30,818
27,347
24,652
48,983
44,050
60,797
58,299
55,780
50,547
46,936
86,344
83,900
76,742
75,934
70,749
67,850
60,878
54,938
51,383
87,439
79,355
72,105
65,889
62,999
52,537
95,621
88,310
87,336
90,424
86,312
81,813
82,533
75,844
74,196
140,366
140,838
255,500
250,837
247,347
243,212
238,505
229,948
232,516
217,235
197,048
180,906
164,978
157,891
146,810
282,993
269,791
286,741
281,168
627,727
606,604
590,395
542,729
673,481
640,222
637,516
584,276
894,659
963,710
938,550
877,095
835,363
772,398
721,923
654,310
617,126
593,913
562,509
440,567
325,074
219,697
165,320
165,320219,697325,074440,567562,509593,913617,126654,310721,923772,398835,363877,095938,550963,710894,659584,276637,516640,222673,481542,729590,395606,604627,727281,168286,741269,791282,993146,810157,891164,978180,906197,048217,235232,516229,948238,505243,212247,347250,837255,500140,838140,36674,19675,84482,53381,81386,31290,42487,33688,31095,62152,53762,99965,88972,10579,35587,43951,38354,93860,87867,85070,74975,93476,74283,90086,34446,93650,54755,78058,29960,79744,05048,98324,65227,34730,81834,72536,35840,36143,26646,23248,10150,04552,72056,22756,02877,20380,71785,01786,89665,50067,94268,92569,05769,79322,950
   > Total Current Assets 
21,929
56,283
49,939
66,512
65,207
62,505
65,390
63,770
59,804
56,335
53,667
54,096
50,807
48,697
46,961
45,285
42,495
39,795
35,939
34,376
30,521
26,932
24,274
48,462
43,364
60,231
57,767
55,056
49,747
45,754
84,991
82,118
74,709
73,860
68,633
65,852
58,969
53,135
49,685
85,773
77,464
69,276
64,090
61,314
47,894
94,030
86,704
85,692
81,824
63,662
62,391
68,365
61,546
53,721
126,143
97,274
220,212
202,980
173,169
190,879
203,946
221,005
227,683
212,582
191,138
176,150
148,845
149,580
133,774
255,677
242,340
248,397
236,276
550,049
468,202
410,521
362,628
461,808
384,176
405,473
370,948
679,400
700,294
659,668
606,944
554,064
447,396
398,769
340,065
343,120
336,621
300,327
227,087
159,609
147,576
94,328
94,328147,576159,609227,087300,327336,621343,120340,065398,769447,396554,064606,944659,668700,294679,400370,948405,473384,176461,808362,628410,521468,202550,049236,276248,397242,340255,677133,774149,580148,845176,150191,138212,582227,683221,005203,946190,879173,169202,980220,21297,274126,14353,72161,54668,36562,39163,66281,82485,69286,70494,03047,89461,31464,09069,27677,46485,77349,68553,13558,96965,85268,63373,86074,70982,11884,99145,75449,74755,05657,76760,23143,36448,46224,27426,93230,52134,37635,93939,79542,49545,28546,96148,69750,80754,09653,66756,33559,80463,77065,39062,50565,20766,51249,93956,28321,929
       Cash And Cash Equivalents 
10,592
39,586
9,145
10,151
16,051
15,162
21,205
7,644
32,010
33,058
15,348
17,639
12,587
9,803
12,104
9,803
9,511
7,784
6,621
8,626
7,620
7,708
10,527
18,507
13,398
28,838
16,117
12,702
11,030
9,672
16,894
12,275
9,942
8,658
8,743
19,409
14,643
14,774
14,099
21,159
12,204
12,789
9,055
10,784
6,879
8,421
21,667
16,766
24,490
18,476
13,724
21,679
12,177
12,052
80,309
10,186
126,823
99,270
11,205
6,030
25,256
10,768
34,287
69,482
33,009
12,955
27,986
22,061
18,486
69,837
29,894
49,826
30,708
59,406
39,298
140,418
80,968
169,222
114,291
80,428
85,749
467,443
259,393
131,329
122,975
169,878
176,954
178,872
120,257
117,705
94,570
100,444
78,241
66,830
56,514
45,204
45,20456,51466,83078,241100,44494,570117,705120,257178,872176,954169,878122,975131,329259,393467,44385,74980,428114,291169,22280,968140,41839,29859,40630,70849,82629,89469,83718,48622,06127,98612,95533,00969,48234,28710,76825,2566,03011,20599,270126,82310,18680,30912,05212,17721,67913,72418,47624,49016,76621,6678,4216,87910,7849,05512,78912,20421,15914,09914,77414,64319,4098,7438,6589,94212,27516,8949,67211,03012,70216,11728,83813,39818,50710,5277,7087,6208,6266,6217,7849,5119,80312,1049,80312,58717,63915,34833,05832,0107,64421,20515,16216,05110,1519,14539,58610,592
       Short-term Investments 
10,931
15,903
39,961
53,359
46,745
44,662
42,017
53,950
26,772
21,920
36,587
34,504
36,474
37,538
33,724
34,052
32,138
30,623
28,418
24,634
22,179
18,099
13,089
28,449
29,140
30,330
40,763
41,218
37,972
34,895
67,045
68,813
63,468
55,389
50,496
45,422
43,053
37,487
33,591
63,781
64,334
56,201
53,687
49,501
38,875
83,066
62,781
67,366
55,206
41,167
44,178
41,868
45,088
35,224
39,913
82,627
86,607
94,386
151,219
172,932
170,647
203,462
185,042
139,518
154,572
159,321
117,595
120,474
110,780
180,074
206,810
193,482
198,818
480,040
419,272
259,715
270,028
271,877
240,561
282,046
272,381
197,410
389,434
510,094
464,109
359,775
246,459
197,676
197,539
198,017
218,998
177,188
127,146
76,271
75,597
35,798
35,79875,59776,271127,146177,188218,998198,017197,539197,676246,459359,775464,109510,094389,434197,410272,381282,046240,561271,877270,028259,715419,272480,040198,818193,482206,810180,074110,780120,474117,595159,321154,572139,518185,042203,462170,647172,932151,21994,38686,60782,62739,91335,22445,08841,86844,17841,16755,20667,36662,78183,06638,87549,50153,68756,20164,33463,78133,59137,48743,05345,42250,49655,38963,46868,81367,04534,89537,97241,21840,76330,33029,14028,44913,08918,09922,17924,63428,41830,62332,13834,05233,72437,53836,47434,50436,58721,92026,77253,95042,01744,66246,74553,35939,96115,90310,931
       Net Receivables 
293
362
595
2,677
2,189
2,156
1,835
1,729
650
722
1,281
1,530
1,364
594
620
1,146
641
744
433
829
433
454
190
1,189
492
398
383
542
226
178
237
533
782
9,226
9,012
694
1,033
338
1,563
410
584
548
865
703
1,862
1,890
1,695
1,250
1,878
3,440
3,815
4,319
3,925
5,191
5,088
3,493
5,743
7,280
8,787
10,791
7,036
5,572
7,403
2,828
2,969
2,604
1,792
5,196
2,799
3,751
3,916
3,583
3,948
5,539
6,250
5,048
7,905
12,861
22,633
37,591
7,896
6,152
40,309
6,259
7,720
7,689
8,587
6,362
7,294
6,291
5,046
4,472
8,049
3,935
1,750
1,326
1,3261,7503,9358,0494,4725,0466,2917,2946,3628,5877,6897,7206,25940,3096,1527,89637,59122,63312,8617,9055,0486,2505,5393,9483,5833,9163,7512,7995,1961,7922,6042,9692,8287,4035,5727,03610,7918,7877,2805,7433,4935,0885,1913,9254,3193,8153,4401,8781,2501,6951,8901,8627038655485844101,5633381,0336949,0129,2267825332371782265423833984921,1891904544338294337446411,1466205941,3641,5301,2817226501,7291,8352,1562,1892,677595362293
       Other Current Assets 
113
432
238
325
222
525
333
447
372
635
451
423
382
762
513
284
205
644
467
287
289
671
468
317
334
665
504
594
519
1,009
815
497
517
587
382
327
240
536
432
423
342
697
483
326
278
653
561
310
250
579
674
203
120
285
149
191
349
671
887
183
100
114
951
754
588
1,270
1,472
1,849
1,709
2,015
1,720
1,506
2,802
5,064
3,382
5,340
3,727
5,848
4,691
5,408
4,922
8,395
11,158
11,986
12,140
16,722
15,396
15,859
14,975
21,107
18,007
18,223
13,651
12,573
13,715
12,000
12,00013,71512,57313,65118,22318,00721,10714,97515,85915,39616,72212,14011,98611,1588,3954,9225,4084,6915,8483,7275,3403,3825,0642,8021,5061,7202,0151,7091,8491,4721,2705887549511141001838876713491911492851202036745792503105616532783264836973424234325362403273825875174978151,009519594504665334317468671289287467644205284513762382423451635372447333525222325238432113
   > Long-term Assets 
1,021
13,510
19,118
2,413
2,735
2,995
21,506
21,247
20,913
20,868
2,361
2,131
1,913
1,348
1,140
947
771
566
419
349
297
415
378
521
686
566
532
724
800
1,182
1,353
1,782
2,033
2,074
2,116
1,998
1,909
1,803
1,698
1,666
1,891
2,829
1,799
1,685
4,643
1,591
1,606
1,644
8,600
22,650
19,422
14,168
14,298
20,475
14,223
43,564
35,288
47,857
74,178
52,333
34,559
8,943
4,833
4,653
5,910
4,756
16,133
8,311
13,036
27,316
27,451
38,344
44,892
77,678
138,402
179,874
180,101
211,673
256,046
232,043
213,328
215,259
263,416
278,882
270,151
281,299
325,002
323,154
314,245
274,006
257,292
262,182
213,480
165,465
72,121
70,992
70,99272,121165,465213,480262,182257,292274,006314,245323,154325,002281,299270,151278,882263,416215,259213,328232,043256,046211,673180,101179,874138,40277,67844,89238,34427,45127,31613,0368,31116,1334,7565,9104,6534,8338,94334,55952,33374,17847,85735,28843,56414,22320,47514,29814,16819,42222,6508,6001,6441,6061,5914,6431,6851,7992,8291,8911,6661,6981,8031,9091,9982,1162,0742,0331,7821,3531,1828007245325666865213784152973494195667719471,1401,3481,9132,1312,36120,86820,91321,24721,5062,9952,7352,41319,11813,5101,021
       Property Plant Equipment 
727
1,377
1,503
1,982
2,291
2,697
2,937
2,799
2,586
2,403
2,027
1,793
1,591
1,294
1,089
906
720
534
387
318
268
349
310
472
637
517
483
675
751
1,133
1,304
1,770
2,021
2,062
2,104
1,986
1,897
1,791
1,686
1,654
1,879
1,858
1,787
1,673
1,620
1,550
1,565
1,603
1,653
1,532
1,467
1,543
1,464
1,587
1,494
1,406
1,410
1,622
1,566
1,479
2,995
3,217
3,063
2,916
3,176
3,025
4,882
6,557
7,267
8,347
8,500
31,066
33,601
37,223
50,497
78,723
46,471
100,454
104,021
107,215
106,671
107,408
106,919
112,369
115,546
117,892
117,043
124,704
122,499
122,196
120,942
125,533
108,573
107,490
55,647
52,865
52,86555,647107,490108,573125,533120,942122,196122,499124,704117,043117,892115,546112,369106,919107,408106,671107,215104,021100,45446,47178,72350,49737,22333,60131,0668,5008,3477,2676,5574,8823,0253,1762,9163,0633,2172,9951,4791,5661,6221,4101,4061,4941,5871,4641,5431,4671,5321,6531,6031,5651,5501,6201,6731,7871,8581,8791,6541,6861,7911,8971,9862,1042,0622,0211,7701,3041,1337516754835176374723103492683183875347209061,0891,2941,5911,7932,0272,4032,5862,7992,9372,6972,2911,9821,5031,377727
       Goodwill 
0
0
0
0
0
0
15,250
15,250
15,250
15,250
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
40,044
39,283
39,795
38,270
39,273
38,550
39,318
40,984
42,798
40,994
41,501
40,530
39,702
38,935
36,702
34,511
37,552
0
0
0
0
000037,55234,51136,70238,93539,70240,53041,50140,99442,79840,98439,31838,55039,27338,27039,79539,28340,0441,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,58500000000000000000000000000000000000000000000015,25015,25015,25015,250000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,690
38,663
30,384
42,741
69,049
47,260
29,822
3,948
0
0
1,003
0
9,507
0
2,995
16,343
16,325
1,012
4,986
34,182
0
0
0
8,450
52,789
21,832
5,000
0
45,761
50,530
42,431
49,205
95,631
88,169
82,515
47,966
36,700
29,845
35,610
39,037
0
0
0039,03735,61029,84536,70047,96682,51588,16995,63149,20542,43150,53045,76105,00021,83252,7898,45000034,1824,9861,01216,32516,3432,99509,50701,003003,94829,82247,26069,04942,74130,38438,66312,690000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
18,490
18,370
18,250
18,130
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,870
1,870
1,870
1,870
1,870
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
1,585
54,866
53,170
53,892
51,741
53,156
52,137
53,219
55,569
58,128
55,583
56,298
54,928
53,760
52,679
49,529
46,439
50,729
51,555
0
0
0
00051,55550,72946,43949,52952,67953,76054,92856,29855,58358,12855,56953,21952,13753,15651,74153,89253,17054,8661,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,5851,8701,8701,8701,8701,87000000000000000000000000000000000000000000000018,13018,25018,37018,490000000
       Other Assets 
294
12,133
17,615
431
444
298
18,569
18,448
18,327
18,465
334
338
322
54
51
41
51
32
32
31
29
66
68
49
49
49
49
49
49
49
49
12
12
12
12
12
12
12
12
12
12
12
12
12
3,023
41
41
41
6,947
21,118
17,955
12,625
12,834
18,888
12,729
42,158
33,878
46,235
72,612
50,854
31,564
5,726
1,770
1,737
2,734
1,731
11,251
1,754
5,769
18,969
18,951
7,278
4,720
4,688
86,320
6,241
41,177
9,082
9,225
10,567
10,970
15,314
14,183
15,057
15,597
16,403
16,870
16,819
17,617
17,613
18,700
18,523
17,742
18,938
0
0
0018,93817,74218,52318,70017,61317,61716,81916,87016,40315,59715,05714,18315,31410,97010,5679,2259,08241,1776,24186,3204,6884,7207,27818,95118,9695,7691,75411,2511,7312,7341,7371,7705,72631,56450,85472,61246,23533,87842,15812,72918,88812,83412,62517,95521,1186,9474141413,0231212121212121212121212121249494949494949496866293132325141515432233833418,46518,32718,44818,56929844443117,61512,133294
> Total Liabilities 
14,090
1,077
921
2,035
2,083
1,130
2,468
2,668
2,031
1,552
1,466
1,981
1,279
1,735
2,163
1,571
915
1,043
1,389
2,348
1,764
1,416
2,205
11,169
8,475
7,663
7,364
7,075
6,592
7,002
10,520
11,778
10,285
15,321
14,728
12,454
10,887
7,762
6,933
15,657
9,341
3,637
4,250
7,092
3,378
4,009
4,144
7,204
16,084
16,083
15,411
17,637
14,258
14,818
14,225
19,128
38,075
36,480
37,208
36,579
31,017
30,004
28,958
24,796
17,641
20,883
21,142
21,696
21,127
88,953
83,139
98,841
98,803
239,860
226,698
223,877
213,548
227,733
220,894
204,777
189,861
383,453
442,829
441,184
407,678
389,906
366,382
346,580
319,788
298,845
284,759
267,551
104,957
91,432
84,775
82,433
82,43384,77591,432104,957267,551284,759298,845319,788346,580366,382389,906407,678441,184442,829383,453189,861204,777220,894227,733213,548223,877226,698239,86098,80398,84183,13988,95321,12721,69621,14220,88317,64124,79628,95830,00431,01736,57937,20836,48038,07519,12814,22514,81814,25817,63715,41116,08316,0847,2044,1444,0093,3787,0924,2503,6379,34115,6576,9337,76210,88712,45414,72815,32110,28511,77810,5207,0026,5927,0757,3647,6638,47511,1692,2051,4161,7642,3481,3891,0439151,5712,1631,7351,2791,9811,4661,5522,0312,6682,4681,1302,0832,0359211,07714,090
   > Total Current Liabilities 
1,471
1,077
921
2,035
2,083
1,130
2,148
2,668
2,031
1,552
1,466
1,981
1,279
1,735
2,163
1,571
915
1,043
1,389
2,348
1,764
1,416
2,205
6,794
4,725
4,538
4,864
5,200
4,842
6,273
8,045
9,681
8,584
12,519
13,576
11,631
10,503
7,707
6,933
15,657
9,341
3,637
4,250
7,092
3,378
4,009
4,144
7,204
5,612
6,152
6,022
8,790
5,953
7,055
7,004
10,131
16,406
16,799
19,494
20,882
19,968
21,056
22,128
20,097
10,094
14,460
13,868
13,291
13,064
41,657
42,943
44,859
49,390
75,949
74,123
78,511
91,127
82,045
80,550
69,872
62,065
93,942
123,561
143,547
132,839
136,943
131,898
127,887
118,526
119,987
122,361
111,711
57,839
53,792
48,482
47,731
47,73148,48253,79257,839111,711122,361119,987118,526127,887131,898136,943132,839143,547123,56193,94262,06569,87280,55082,04591,12778,51174,12375,94949,39044,85942,94341,65713,06413,29113,86814,46010,09420,09722,12821,05619,96820,88219,49416,79916,40610,1317,0047,0555,9538,7906,0226,1525,6127,2044,1444,0093,3787,0924,2503,6379,34115,6576,9337,70710,50311,63113,57612,5198,5849,6818,0456,2734,8425,2004,8644,5384,7256,7942,2051,4161,7642,3481,3891,0439151,5712,1631,7351,2791,9811,4661,5522,0312,6682,1481,1302,0832,0359211,0771,471
       Short-term Debt 
0
0
0
0
0
0
0
285
536
234
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,396
0
0
0
2,897
0
0
0
2,355
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,552
0
0
0
6,032
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,320
0
0
3,214
0
0
0
3,690
0
0
0
4,026
0
0
0
4,122
0
0
0
4,589
4,5890004,1220004,0260003,6900003,214001,32000000000000000006,0320004,55200000000000000000002,3550002,8970001,396000000000000000002345362850000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,320
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001,3200000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
112
38
128
634
250
185
798
1,261
939
541
603
937
494
955
1,290
815
418
522
739
906
628
462
907
1,534
794
953
1,156
1,108
1,530
2,768
1,830
1,554
4,112
2,611
3,243
1,691
3,868
2,544
2,283
1,311
2,026
1,629
2,653
3,537
2,508
3,651
3,823
4,110
3,441
3,944
3,576
3,046
3,667
4,737
4,704
3,022
7,583
7,682
10,663
5,525
8,509
11,532
11,667
3,905
4,833
9,216
9,154
2,580
9,464
12,115
14,586
16
10,970
14,388
16,424
3,355
30,135
31,219
32,989
6,671
25,515
32,553
35,770
12,553
11,638
10,132
7,982
9,759
11,147
13,076
17,380
22,418
19,920
14,837
15,457
15,259
15,25915,45714,83719,92022,41817,38013,07611,1479,7597,98210,13211,63812,55335,77032,55325,5156,67132,98931,21930,1353,35516,42414,38810,9701614,58612,1159,4642,5809,1549,2164,8333,90511,66711,5328,5095,52510,6637,6827,5833,0224,7044,7373,6673,0463,5763,9443,4414,1103,8233,6512,5083,5372,6531,6292,0261,3112,2832,5443,8681,6913,2432,6114,1121,5541,8302,7681,5301,1081,1569537941,5349074626289067395224188151,2909554949376035419391,26179818525063412838112
       Other Current Liabilities 
1,359
1,039
793
1,401
1,833
220
662
671
250
513
652
669
436
458
578
636
411
468
624
657
412
475
648
933
496
602
835
100
588
644
902
286
742
841
1,243
190
4,705
3,527
3,676
3,843
2,813
2,594
4,104
7,011
3,374
3,651
3,823
2,946
3,441
3,944
3,576
3,440
3,667
4,737
4,704
275
7,858
7,957
10,938
275
8,784
11,532
11,667
7,072
4,833
9,216
9,154
6,566
9,464
12,115
14,586
16,498
3,211
4,346
6,605
27,592
6,168
31,219
32,989
21,276
25,515
32,553
35,770
30,660
26,837
32,854
33,462
28,391
26,596
28,117
33,091
33,391
28,344
32,082
31,540
27,883
27,88331,54032,08228,34433,39133,09128,11726,59628,39133,46232,85426,83730,66035,77032,55325,51521,27632,98931,2196,16827,5926,6054,3463,21116,49814,58612,1159,4646,5669,1549,2164,8337,07211,66711,5328,78427510,9387,9577,8582754,7044,7373,6673,4403,5763,9443,4412,9463,8233,6513,3747,0114,1042,5942,8133,8433,6763,5274,7051901,2438417422869026445881008356024969336484754126576244684116365784584366696525132506716622201,8331,4017931,0391,359
   > Long-term Liabilities 
12,619
0
0
0
0
0
320
300
200
300
0
1,606
0
0
0
1,451
0
0
0
1,563
0
0
0
4,375
3,750
3,125
2,500
1,875
1,750
729
2,475
2,097
1,701
2,802
1,152
823
384
55
0
0
0
3,637
0
0
0
0
0
0
10,472
9,931
9,389
8,847
8,305
7,763
7,221
8,997
21,669
19,681
17,714
15,697
11,049
8,948
6,830
4,699
7,547
6,423
7,274
8,405
8,063
47,296
40,196
53,982
49,413
163,911
152,575
144,627
122,421
145,688
140,344
134,905
127,796
289,511
319,268
297,637
274,839
252,963
234,484
218,693
201,262
178,858
162,398
155,840
47,118
37,640
36,293
34,702
34,70236,29337,64047,118155,840162,398178,858201,262218,693234,484252,963274,839297,637319,268289,511127,796134,905140,344145,688122,421144,627152,575163,91149,41353,98240,19647,2968,0638,4057,2746,4237,5474,6996,8308,94811,04915,69717,71419,68121,6698,9977,2217,7638,3058,8479,3899,93110,4720000003,637000553848231,1522,8021,7012,0972,4757291,7501,8752,5003,1253,7504,3750001,5630001,4510001,60603002003003200000012,619
       Long term Debt 
12,619
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
213
247
2,256
3,945
3,928
3,887
3,870
24,738
25,449
26,180
26,928
0
13,299
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000013,299026,92826,18025,44924,7383,8703,8873,9283,9452,25624721300000000000000000000000000000000000000000000000000000000000000012,619
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
-285
-536
-234
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,396
0
0
0
-2,897
0
0
0
-2,355
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-4,552
0
0
0
-6,032
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,979
41,550
40,609
41,192
40,198
39,234
38,259
38,396
38,463
37,328
36,121
44,055
42,815
41,530
39,705
38,986
37,701
36,373
34,975
33,515
33,51534,97536,37337,70138,98639,70541,53042,81544,05536,12137,32838,46338,39638,25939,23440,19841,19240,60941,55011,9790000000000000000-6,032000-4,5520000000000000000000-2,355000-2,897000-1,39600000000000000000-234-536-2850000000
       Other Liabilities 
0
0
0
0
0
0
320
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,375
3,750
3,125
2,500
1,875
1,750
729
2,475
2,097
1,701
2,802
1,152
823
384
55
0
0
0
0
0
0
0
0
0
0
10,472
9,931
9,389
8,847
8,305
7,763
7,221
8,249
20,921
18,933
16,966
14,949
11,049
8,948
6,830
4,699
7,334
6,176
5,018
4,460
4,135
43,409
36,326
29,244
49,413
163,911
152,575
144,627
109,122
104,138
99,735
93,713
87,598
250,277
281,009
259,241
236,376
215,635
198,363
174,638
158,447
137,328
122,693
116,854
9,417
1,267
0
0
001,2679,417116,854122,693137,328158,447174,638198,363215,635236,376259,241281,009250,27787,59893,71399,735104,138109,122144,627152,575163,91149,41329,24436,32643,4094,1354,4605,0186,1767,3344,6996,8308,94811,04914,94916,96618,93320,9218,2497,2217,7638,3058,8479,3899,93110,4720000000000553848231,1522,8021,7012,0972,4757291,7501,8752,5003,1253,7504,3750000000000000000320000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,570
1,620
1,650
1,700
1,800
0
0
0
0
213
247
2,256
3,945
3,928
3,887
3,870
24,738
25,449
163,911
152,575
137,922
115,849
139,027
133,949
128,335
121,352
282,933
312,400
290,452
267,969
7,425
227,695
212,048
194,751
172,736
156,658
149,570
40,746
37,640
1,318
1,187
1,1871,31837,64040,746149,570156,658172,736194,751212,048227,6957,425267,969290,452312,400282,933121,352128,335133,949139,027115,849137,922152,575163,91125,44924,7383,8703,8873,9283,9452,25624721300001,8001,7001,6501,6201,5700000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,472
0
0
8,847
8,305
7,763
7,221
7,427
20,049
18,031
16,014
13,897
11,049
8,948
6,830
4,699
7,334
6,176
5,018
4,460
4,135
43,409
36,326
29,244
23,964
0
0
6,705
6,572
6,661
6,395
6,570
6,444
6,578
6,868
7,185
6,870
6,959
6,789
6,645
6,511
6,122
5,740
6,270
6,372
0
0
0
0006,3726,2705,7406,1226,5116,6456,7896,9596,8707,1856,8686,5786,4446,5706,3956,6616,5726,7050023,96429,24436,32643,4094,1354,4605,0186,1767,3344,6996,8308,94811,04913,89716,01418,03120,0497,4277,2217,7638,3058,8470010,472000000000000000000000000000000000000000000000000
> Total Stockholder Equity
8,860
68,716
68,136
66,890
65,859
64,370
84,428
82,349
78,686
75,651
54,562
54,246
51,441
48,310
45,938
44,661
42,351
39,318
34,969
32,377
29,054
25,931
22,447
37,814
35,575
53,134
50,935
48,705
43,955
39,934
75,824
72,122
66,457
60,613
56,021
55,396
49,991
47,176
44,450
71,782
70,014
68,468
61,639
55,907
49,159
91,612
84,166
80,132
74,340
70,229
66,402
64,896
61,586
59,378
126,141
121,710
217,425
214,357
210,139
206,633
207,488
199,944
203,558
192,439
179,407
160,023
143,836
136,195
125,683
194,040
186,652
187,900
182,365
387,867
379,906
366,518
328,495
445,134
419,089
432,739
394,291
511,457
521,411
497,366
470,355
445,457
406,016
375,343
334,522
318,281
309,154
294,958
335,610
233,642
134,922
82,887
82,887134,922233,642335,610294,958309,154318,281334,522375,343406,016445,457470,355497,366521,411511,457394,291432,739419,089445,134328,495366,518379,906387,867182,365187,900186,652194,040125,683136,195143,836160,023179,407192,439203,558199,944207,488206,633210,139214,357217,425121,710126,14159,37861,58664,89666,40270,22974,34080,13284,16691,61249,15955,90761,63968,46870,01471,78244,45047,17649,99155,39656,02160,61366,45772,12275,82439,93443,95548,70550,93553,13435,57537,81422,44725,93129,05432,37734,96939,31842,35144,66145,93848,31051,44154,24654,56275,65178,68682,34984,42864,37065,85966,89068,13668,7168,860
   Common Stock
10,337
88,311
88,359
89,764
90,036
90,301
127,035
127,161
127,093
127,090
127,005
127,234
127,245
127,326
127,502
127,927
128,509
128,897
129,047
129,482
129,654
129,906
130,089
148,162
31
34
34
350
350
352
399
403
408
409
410
410
411
411
413
450
451
452
452
454
456
524
525
526
526
527
529
531
535
540
614
622
678
681
683
690
695
698
700
703
704
706
706
709
718
835
841
856
870
1,016
1,018
1,022
1,023
1,156
1,158
1,160
1,163
1,410
1,412
1,421
1,437
1,451
1,455
1,459
1,467
1,534
1,619
1,668
1,718
1,771
1,773
1,781
1,7811,7731,7711,7181,6681,6191,5341,4671,4591,4551,4511,4371,4211,4121,4101,1631,1601,1581,1561,0231,0221,0181,016870856841835718709706706704703700698695690683681678622614540535531529527526526525524456454452452451450413411411410410409408403399352350350343431148,162130,089129,906129,654129,482129,047128,897128,509127,927127,502127,326127,245127,234127,005127,090127,093127,161127,03590,30190,03689,76488,35988,31110,337
   Retained Earnings -1,406,376-1,346,081-1,241,918-1,127,412-1,148,545-1,096,572-1,043,417-1,000,244-956,267-918,771-871,083-823,914-777,981-737,377-735,827-699,898-656,985-661,540-634,233-603,949-562,696-544,032-531,189-514,549-495,479-482,388-470,034-457,543-440,911-431,287-412,322-385,747-369,253-355,240-345,995-333,869-328,550-324,231-316,686-309,705-302,133-293,989-287,844-282,394-275,509-272,031-266,241-260,513-253,245-246,886-237,332-227,073-217,495-209,174-200,479-196,619-192,641-190,248-185,397-180,886-174,054-171,480-165,140-157,724-149,752-143,080-138,812-133,631-128,272-119,324-116,479-113,152-110,408-107,715-104,048-100,668-97,115-94,072-89,501-86,239-83,297-81,617-79,033-75,759-72,864-72,158-51,218-47,587-43,100-39,734-22,331-19,913-17,851-15,046-13,232-11,503
   Accumulated Other Comprehensive Income 
-6,661
-6,363
-5,177
-5,023
-4,264
-3,600
-2,873
-1,712
-820
-221
-285
-124
-45
17
53
31
81
-78
-6
10
68
73
73
60
49
31
107
114
112
130
239
295
405
150
197
276
197
121
63
18
1
14
3
-6
14
17
-2
12
-3
-7
15
26
25
-1
26
12
21
33
53
-25
25
-3
54
-4,846
83
91
77
20
-92
-143
-131
-286
-385
-157
-244
-1,440
-2,691
-765
-4,901
-2,449
-3,828
-1,653
1,553
5,419
714
1,987
-623
-3,987
-6,955
-13,160
-18,998
-8,404
-5,758
-5,936
-6,581
-4,595
-4,595-6,581-5,936-5,758-8,404-18,998-13,160-6,955-3,987-6231,9877145,4191,553-1,653-3,828-2,449-4,901-765-2,691-1,440-244-157-385-286-131-143-9220779183-4,84654-325-255333211226-1252615-7-312-21714-63141186312119727619715040529523913011211410731496073736810-6-7881315317-45-124-285-221-820-1,712-2,873-3,600-4,264-5,023-5,177-6,363-6,661
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
328,403
330,529
332,839
334,330
335,950
337,889
339,848
343,420
346,683
419,490
423,209
526,431
530,329
533,634
534,518
540,637
545,244
558,044
560,989
564,367
571,548
574,340
576,377
582,600
663,382
668,330
682,809
696,429
918,197
923,164
929,632
934,112
1,078,976
1,084,372
1,090,828
1,096,854
1,247,527
1,255,823
1,269,375
1,292,118
1,313,102
1,323,955
1,334,138
1,340,254
1,373,324
1,423,105
1,450,239
1,467,062
1,479,725
0
0
001,479,7251,467,0621,450,2391,423,1051,373,3241,340,2541,334,1381,323,9551,313,1021,292,1181,269,3751,255,8231,247,5271,096,8541,090,8281,084,3721,078,976934,112929,632923,164918,197696,429682,809668,330663,382582,600576,377574,340571,548564,367560,989558,044545,244540,637534,518533,634530,329526,431423,209419,490346,683343,420339,848337,889335,950334,330332,839330,529328,403000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue176,232
Cost of Revenue-22,192
Gross Profit154,040154,040
 
Operating Income (+$)
Gross Profit154,040
Operating Expense-268,332
Operating Income-114,292-114,292
 
Operating Expense (+$)
Research Development230,457
Selling General Administrative61,167
Selling And Marketing Expenses23,292
Operating Expense268,332314,916
 
Net Interest Income (+$)
Interest Income13,288
Interest Expense-0
Other Finance Cost-0
Net Interest Income13,288
 
Pretax Income (+$)
Operating Income-114,292
Net Interest Income13,288
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-262,90334,319
EBIT - interestExpense = -114,292
-262,903
-257,831
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-114,292-262,903
Earnings Before Interest and Taxes (EBITDA)-92,100
 
After tax Income (+$)
Income Before Tax-262,903
Tax Provision--4,541
Net Income From Continuing Ops-249,509-258,362
Net Income-257,831
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses290,524
Total Other Income/Expenses Net-148,611-13,288
 

Technical Analysis of Sangamo
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sangamo. The general trend of Sangamo is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sangamo's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sangamo Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.9782 < 1.48 < 1.6187.

The bearish price targets are: 0.39 > 0.3462 > 0.2911.

Tweet this
Sangamo Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sangamo Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sangamo Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sangamo Therapeutics Inc. The current macd is -0.05540005.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sangamo price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Sangamo. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Sangamo price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Sangamo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartSangamo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sangamo Therapeutics Inc. The current adx is 20.06.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Sangamo shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Sangamo Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sangamo Therapeutics Inc. The current sar is 0.92123666.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Sangamo Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sangamo Therapeutics Inc. The current rsi is 42.57. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Sangamo Therapeutics Inc Daily Relative Strength Index (RSI) ChartSangamo Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sangamo Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sangamo price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Sangamo Therapeutics Inc Daily Stochastic Oscillator ChartSangamo Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sangamo Therapeutics Inc. The current cci is -118.99310714.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Sangamo Therapeutics Inc Daily Commodity Channel Index (CCI) ChartSangamo Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sangamo Therapeutics Inc. The current cmo is -19.86710014.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Sangamo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartSangamo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sangamo Therapeutics Inc. The current willr is -79.54545455.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Sangamo is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Sangamo Therapeutics Inc Daily Williams %R ChartSangamo Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Sangamo Therapeutics Inc.

Sangamo Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sangamo Therapeutics Inc. The current atr is 0.11889189.

Sangamo Therapeutics Inc Daily Average True Range (ATR) ChartSangamo Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sangamo Therapeutics Inc. The current obv is -78,439,914.

Sangamo Therapeutics Inc Daily On-Balance Volume (OBV) ChartSangamo Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sangamo Therapeutics Inc. The current mfi is 18.55.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Sangamo Therapeutics Inc Daily Money Flow Index (MFI) ChartSangamo Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sangamo Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-09STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-10STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-11MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Sangamo Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sangamo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.570
Ma 20Greater thanMa 500.837
Ma 50Greater thanMa 1000.773
Ma 100Greater thanMa 2000.605
OpenGreater thanClose0.625
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Sangamo with someone you think should read this too:
  • Are you bullish or bearish on Sangamo? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sangamo? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sangamo Therapeutics Inc

I send you an email if I find something interesting about Sangamo Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Sangamo Therapeutics Inc.

Receive notifications about Sangamo Therapeutics Inc in your mailbox!